Effects of 4-1BB signaling on the biological function of murine dendritic cells

Kuang,Youlin; Weng,Xiaodong; Liu,Xiuheng; Zhu,Hengchen; Chen,Zhiyuan; Chen,Hui

doi:10.3892/ol.2011.506

Effects of 4-1BB signaling on the biological function of murine dendritic cells

Authors:
- Youlin Kuang
- Xiaodong Weng
- Xiuheng Liu
- Hengchen Zhu
- Zhiyuan Chen
- Hui Chen
View Affiliations

Affiliations: Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China
Published online on: December 1, 2011 https://doi.org/10.3892/ol.2011.506
Pages: 477-481

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

4-1BB signaling has profound effects on the T cell-induced cell immune response, but its biological function in dendritic cells (DCs) has remained largely uncharacterized. In this study, we investigated the function of 4-1BB in murine DCs with an agonistic mAb to 4-1BB. Interleukin (IL)-6 and IL-12 production was assessed by an enzyme-linked immunosorbent assay (ELISA). Co-stimulatory molecules (CD80 and CD86) in DCs were analyzed by ﬂow cytometry. The results showed that 4-1BB was strongly expressed in DCs during the maturation process. Triggering 4-1BB increased the secretion of IL-6 and IL-12 and the upregulation of co-stimulatory molecules (CD80 and CD86) from DCs, indicating that agonistic mAb to 4-1BB directly improves the activation of DCs. Moreover, triggering 4-1BB induced a higher survival rate of DCs compared to that of hamster IgG isotype control, due to the upregulated expression of Bcl-2 and Bcl-xL. To further assess the role of 4-1BB on DCs stimulating T-cell proliferation, allogeneic mixed lymphocyte reactions were analyzed. The agonistic anti‑4-1BB mAb induced a higher T-cell proliferation. These results suggest that 4-1BB affects the duration, DC-T interaction and immunogenicity of DCs.

View Figures

View References

1	Nencioni A, Grünebach F, Schmidt SM, et al: The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol. 65:191–199. 2008. View Article : Google Scholar
2	Palucka K, Ueno H, Fay J and Banchereau J: Dendritic cells and immunity against cancer. J Intern Med. 269:64–73. 2011. View Article : Google Scholar : PubMed/NCBI
3	Nopora A and Brocker T: Bcl-2 controls dendritic cell longevity in vivo. J Immunol. 169:3006–3014. 2002. View Article : Google Scholar : PubMed/NCBI
4	Vinay DS and Kwon BS: Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells. Cell Immunol. 192:63–71. 1999.PubMed/NCBI
5	Laderach D, Movassagh M, Johnson A, Mittler RS and Galy A: 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol. 14:1155–1167. 2002.PubMed/NCBI
6	Lu ZY, Condomines M, Tarte K, et al: B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol. 35:443–453. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J and Kaufman HL: 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine. 24:4975–4986. 2006. View Article : Google Scholar : PubMed/NCBI
8	Xiao H, Huang B, Yuan Y, et al: Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res. 13:1823–1830. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lin GH, Liu Y, Ambagala T, Kwon BS, Ohashi PS and Watts TH: Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One. 5:e110032010. View Article : Google Scholar : PubMed/NCBI
10	Gullo C, Koh LK, Pang WL, Ho KT, Tan SH and Schwarz H: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One. 5:e108452010. View Article : Google Scholar : PubMed/NCBI
11	Melero I, Shuford WW, Newby SA, et al: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 3:682–685. 1997. View Article : Google Scholar : PubMed/NCBI
12	Nagaraj S, Pisarev V, Kinarsky L, et al: Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother. 30:169–179. 2007. View Article : Google Scholar : PubMed/NCBI
13	O’Neill DW: Dendritic cells and T cells in immunotherapy. J Drugs Dermatol. 9:1383–1892. 2010.
14	Bertram EM, Dawicki W and Watts TH: Role of T cell costimulation in anti-viral immunity. Semin Immunol. 16:185–196. 2004. View Article : Google Scholar : PubMed/NCBI
15	Cannons JL, Choi Y and Watts TH: Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol. 165:6193–6204. 2000. View Article : Google Scholar : PubMed/NCBI
16	Cannons JL, Hoeflich KP, Woodgett JR and Watts TH: Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. J Immunol. 163:2990–2998. 1999.PubMed/NCBI